In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole-resistant and -susceptible strains of Trichomonas vaginalis

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 2, 2006, Pages 273-278

  Blaha, C ^a   Duchene M ^b   Aspock H ^a   Walochnik, Julia ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Drug resistance; Protozoa; STD; Treatment

Indexed keywords

METRONIDAZOLE; MILTEFOSINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; IN VITRO STUDY; ISOLATION PROCEDURE; LICENSING; NONHUMAN; NUCLEOTIDE SEQUENCE; SEXUALLY TRANSMITTED DISEASE; TRICHOMONAS VAGINALIS; TRICHOMONIASIS;

ANIMALS; ANTIFUNGAL AGENTS; DNA, FUNGAL; DRUG RESISTANCE, FUNGAL; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, PHASE-CONTRAST; PHOSPHORYLCHOLINE; SPECIES SPECIFICITY; TRICHOMONAS VAGINALIS;

EID: 31544441028     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki417     Document Type: Article

References (37)

1. Hammill MA. Trichomonas vaginalis. ObstetGynecol Clin North Am 1989; 16: 531-40.
2. Aspöck H. Protozoa as causative agents of human diseases: Overview and current problems in Central Europe. In: Die Urtiere. Eine verborgene Welt. Linz: OÖ Landesmuseum, 1994; 219-66.
3. Rein MF. Trichomonas vaginalis. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 4th edn. London: Churchill Livingstone, 1990; 2493-7.
4. Borchardt KA. Trichomonosis. In: Honigberg BM, ed. Trichomonads Parasitic in Humans. New York: Springer, 1997; 3-35.
5. Szarka K, Temesvari P, Kerekes A et al. Neonatal pneumonia caused by Trichomonas vaginalis. Acta Microbiol Immunol Hung 2002; 49: 15-9.
6. Petrin D, Delgaty K, Bhatt R et al. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev 1998; 11: 300-17.
7. Hager WD. Treatment of metronidazole-resistant Trichomonas vaginalis with tinidazole: Case reports of three patients. Sex Transm Dis 2004; 31: 343-5.
8. Kulda J. Trichomonads, hydrogenosomes and drug resistance. Int J Parasitol 1999; 29: 199-212.
9. Lumsden WH, Harrison C, Robertson DH. Treatment failure in Trichomonas vaginalis infections in females. II. In-vitro estimation of the sensitivity of the organism to metronidazole. J Antimicrob Chemother 1988; 21: 555-64.
10. Sobel JD, Nagappan V, Nyirjesy P. Metronidazole-resistant vaginal trichomoniasis - an emerging problem. N Engl J Med 1999; 341: 292-3.
11. Adagu IS, Nolder D, Warhurst DC et al. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J Antimicrob Chemother 2002; 49: 103-11.
12. Bouma MJ, Snowdon D, Fairlamb AH et al. Activity of disulfiram (bis(diethylthiocarbamoyl)disulphide) and ditiocarb (diethyldithiocarbamate) against metronidazole-sensitive and -resistant Trichomonas vaginalis and Tritrichomonas foetus. J Antimicrob Chemother 1998; 42: 817-20.
13. Eibl H, Unger C. Hexadecylphosphocholine: A new and selective antitumor drug. Cancer Treat Rev 1990; 17: 233-42.
14. Unger C, Damenz W, Fleer EA et al. Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. Acta Oncol 1989; 28: 213-7.
15. Croft SL, Neal RA, Pendergast W et al. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 1987; 36: 2633-6.
16. Jha TK, Sundar S, Thakur CP et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341: 1795-800.
17. Kuhlencord A, Maniera T, Eibl H et al. Hexadecylphosphocholine: Oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992; 36: 1630-4.
18. Santa-Rita RM, Santos Barbosa H, Meirelles MN et al. Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Trop 2000; 75: 219-28.
19. Seifert K, Duchene M, Wernsdorfer WH et al. Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. Antimicrob Agents Chemother 2001; 45: 1505-10.
20. Walochnik J, Duchene M, Seifert K et al. Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp. Antimicrob Agents Chemother 2002; 46: 695-701.
21. Diamond LS, Harlow DR, Cunnick CC. A new medium for the axenic cultivation of Entamoeba histolytica and other Entamoeba. Trans R Soc Trop Med Hyg 1978; 72: 431-2.
22. Hugo ER, Stewart VJ, Gast RJ et al. Purification of amoeba mtDNA using the UNSET procedure. In: Soldo AT, Lee JJ, eds. Protocols in Protozoology. Kansas: Allen Press, 1992; D7.1-2.
23. Nicholas KB, Nicholas HB Jr, Deerfield DW II. GeneDoc: Analysis and visualization of genetic variation. Embnet News 1997; 4: 14.
24. Thompson JD, Gibson TJ, Plewniak F et al. The ClustalX windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997; 24: 4876-82.
25. Loiseau PM, Bories C, Sanon A. A new photometric assay with bromocresol purple for testing in vitro antitrichomonal activity in aerobic environment. Arzneimittelforschung 1999; 49: 51-5.
26. Rasoloson D, Tomkova E, Cammack R et al. Metronidazole-resistant strains of Trichomonas vaginalis display increased susceptibility to oxygen. Parasitology 2001; 123: 45-56.
27. Santa-Rita RM, Henriques-Pons A, Barbosa HS et al. Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis. J Antimicrob Chemother 2004; 54: 704-10.
28. Paris C, Loiseau PM, Bories C et al. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2004; 48: 852-9.
29. Van der Sanden MH, Houweling M, Duijsings D et al. Inhibition of phosphatidylcholine synthesis is not the primary pathway in hexadecylphosphocholine-induced apoptosis. Biochim Biophys Acta 2004; 1636: 99-107.
30. Verma NK, Dey CS. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob Agents Chemother 2004; 48: 3010-5.
31. Kaufmann-Kolle P, Fleer EA. Morphological changes of adherent and nonadherent cells by treatment with hexadecylphosphocholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine observed by scanning electron microscopy. Prog Exp Tumor Res 1992; 34: 47-58.
32. Croft SL, Seifert K, Duchene M. Antiprotozoal activities of phospholipid analogues. Mol Biochem Parasitol 2003; 126: 165-72.
33. Geilen CC, Wieder T, Reutter W. Hexadecylphosphocholine inhibits translocation of CTP: choline-phosphate cytidylyltransferase in Madin-Darby canine kidney cells. J Biol Chem 1992; 267: 6719-24.
34. Rakotomanga M, Loiseau PM, Saint-Pierre-Chazalet M. Hexadecylphosphocholine interaction with lipid monolayers. Biochim Biophys Acta 2004; 1661: 212-8.
35. Marschner N, Kotting J, Eibl H et al. Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment. Cancer Chemother Pharmacol 1992; 31: 18-22.
36. Kotting J, Berger MR, Unger C et al. Alkylphosphocholines: Influence of structural variation on biodistribution at antineoplastically active concentrations. Cancer Chemother Pharmacol 1992; 30: 105-12.
37. Schmidt-Ott R, Klenner T, Overath P et al. Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1999; 93: 85-90.